In a previous canine clinical trial of mogamulizumab for bladder cancer, urinary CCL17 was shown to be associated with clinical response.21 We investigated the association of pretreatment urinary CCL17 with the response in dogs with prostate cancer. This evidence concerns the gene CCL17 and urinary bladder carcinoma.